Bringing Allogeneic Gamma Delta CAR T Cell Therapy to Autoimmune Diseases

Adicet is at the forefront of bringing cell therapies to the healthcare providers and patients tackling the toughest to treat autoimmune conditions.

We are here, with you, to usher in this new era.

Just as we saw both excitement and challenges when biologics were first being developed for autoimmune diseases, we see a similar environment today with cell therapies, prompting questions from the field, like: 

  • What can therapeutic success look like for my patients with this new treatment paradigm?
  • I’m bombarded every day with new information about cell therapies and requests for my center to participate in yet another clinical trial – how do I make sense of the various cell therapy approaches?
  • Which specific cell therapy modalities may be a fit for my patients and practice? 

 
meet-and-greet with the Adicet Team.

Schedule a meet-and-greet

The Evolving Treatment Landscape

Current Treatment Gap

  • While there have been significant therapeutic advancements in the clinical management of autoimmune diseases, many patients do not respond to the currently available treatments.1 

  • There is a need for new, readily available, off-the-shelf,  approaches that can achieve sustained, treatment-free remission without the risk of chronic immunosuppression or long-term toxicities.

And, Cell Therapies Are Answering the Call. But There Are Key Distinctions Between the Various Cell Therapies:

 

Exploring Adicet’s Novel Allogeneic Gamma Delta CAR T Cell Platform

  • Adicet’s world class researchers selected gamma delta T cells because they preferentially home to lymphoid tissue and organs, enabling immune reset in peripheral blood and tissue
  • Adicet clinical data demonstrated complete CD19+ B cell depletion in peripheral blood and secondary lymphoid tissue
  • Additionally, data show that targeting CD20 fully depletes the B cell lineage in the peripheral blood, including plasmablasts2
  • From data in our oncology program, no risk of T cell malignancies and reduced risk of CRS and ICANS compared to alpha beta T cell approaches 
  • Because it is allogeneic, no leukapheresis or bridging period for manufacturing is required and the cell therapy can be given on demand, i.e., off-the-shelf.

With its safety profile, robust tissue trafficking and complete B cell depletion in peripheral blood and secondary lymphoid tissue, ADI-001 is uniquely designed to bring sustained, treatment-free remissions for patients with various autoimmune conditions.

One dose of off-the-shelf ADI-001 has the potential to reset the immune system so patients can achieve sustained disease remission, no longer requiring the ongoing challenges associated with many existing therapeutic options.

presentation still

Blake Aftab, Ph.D., Chief Scientific Officer
ADI-001 Clinical Biomarker Data: Demonstrating Robust Trafficking and CD19+ B Cell Depletion in Tissue

1 Schett G, et al. Lancet. 2023;402:2034-2044
2 Furie RA et al. Ann Rheum Dis (2022); Tur C, et al. Ann Rhum Dis (2024)

adi-001 trafficking

adi-001 preferentially traffic

adi-001 depletion chart

adi-001 depletion tissues

adi-001 cd19+ charts

Join Our Oral Presentation
Tuesday, Nov 19, 12:00 – 12:15 PM, WCC Room 144ABC

ADI-001: An Allogeneic CD20-targeted É£δ CAR T Cell Therapy with Potential for Improved Tissue Homing in Autoimmune Indications
(Abstract ID: 1866169)

About the ADI-001 Study

ADI-001 is an investigational allogeneic gamma delta chimeric antigen receptor (CAR) T cell therapy targeting CD20 for the treatment of autoimmune diseases.  

ADI-001 was granted Fast Track Designation by the FDA for the treatment of relapsed/refractory class III or class IV lupus nephritis (LN), and the ongoing Phase 1 study is also evaluating ADI-001 for the treatment of systemic lupus erythematosus (SLE), systemic sclerosis (SSc), idiopathic inflammatory myopathy (IIM, or myositis), anti-neutrophil cytoplasmic autoantibody (ANCA)-associated vasculitis (AAV), and stiff person syndrome (SPS).

In the Phase 1 GLEAN trial, ADI-001 was shown to target B-cells via an anti-CD20 CAR and demonstrated robust exposure and complete CD19+ B-cell depletion both in peripheral blood and secondary lymphoid tissue.

adi-001 study

adi-001 endpoints

About Adicet

Adicet is a clinical stage biotechnology company discovering and developing allogeneic gamma delta CAR T cell therapies for autoimmune diseases and cancer.

Specifically in the autoimmune space, our world class researchers and clinicians are putting their decades of experience behind advancing this novel platform to address the underlying mechanisms of autoimmune diseases. The goal is to potentially reset the immune system and achieve sustained treatment-free remission for patients.

We’re passionate about supporting the rheumatology community, advancing the study of cell therapy, and specifically advancing the study of ADI-001 in systemic lupus erythematosus (SLE), lupus nephritis (LN), systemic sclerosis (SSc), idiopathic inflammatory myopathy (IIM, or myositis), anti-neutrophil cytoplasmic autoantibody (ANCA)-associated vasculitis (AAV), and stiff person syndrome (SPS).

Schedule a meet-and-greet with the Adicet Team.

schedule a meet-and-greet